Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis

International Immunopharmacology

Volumn 11, Issue 4, 2011, Pages 519-524

  Zhao, C B ^a   Zhang, X ^b   Zhang, H ^c   Hu, X Q ^d   Lu, J H ^a   Lu, C Z ^a   Xiao, B G ^a  

^a FUDAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Immunomodulation; Myasthenia gravis; Tacrolimus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALOPECIA; ANEMIA; ANKLE EDEMA; ARTICLE; B LYMPHOCYTE; BACKACHE; CD4 CD8 RATIO; CD4+ CD25+ T LYMPHOCYTE; CHINESE; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DENDRITIC CELL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MANUAL MUSCLE TESTING; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE EXAMINATION; MYASTHENIA GRAVIS; ONYCHOMYCOSIS; OSSERMAN GRADE; PARESTHESIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE MYASTHENIA GRAVIS SCORE; RASH; RATING SCALE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TH1 CELL; TH2 CELL;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PILOT PROJECTS; T-LYMPHOCYTES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952738408     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.12.012     Document Type: Article

References (43)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
2. Conti-Fine BM, Milani M, Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann NY Acad Sci 2008;1132:193-209. (Pubitemid 351858541)
3. Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009;65:67-75.
4. Zhang GX, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997;20:543-51. (Pubitemid 27190745)
5. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004;24:17-20.
6. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-90.
7. Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 2008;5:535-41.
8. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-42.
9. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803-7. (Pubitemid 21912434)
10. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol 2005;53:146-50. (Pubitemid 40864306)
11. Ponseti JM, Azem J, Fort JM, López-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005;64:1641-3. (Pubitemid 40617711)
12. Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76:448-50. (Pubitemid 40299146)
13. Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-73. (Pubitemid 39120791)
14. Wakata N, Saito T, Tanaka S, Hirano T, Oka K. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 2003;106:5-8. (Pubitemid 37468493)
15. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-4. (Pubitemid 37339910)
16. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002;9:627-8. (Pubitemid 35364731)
17. Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 2006;247:17-20. (Pubitemid 44107375)
18. Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol 2000;22: 40-3. (Pubitemid 30045603)
19. Jaretzki 3rd A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70:327-34.
20. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-9. (Pubitemid 32059659)
21. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-9. (Pubitemid 29190546)
22. Klein U, Rajewsky K, Küppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-89. (Pubitemid 28516113)
23. Fung E, Esposito L, Todd JA, Wicker LS. Multiplexed immunophenotyping of human antigen-presenting cells in whole blood by polychromatic flow cytometry. Nat Protoc 2010;5:357-70.
24. Duddridge M, Powell RJ. Treatment of severe and dif.cult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997;56: 690-2. (Pubitemid 28007929)
25. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9. (Pubitemid 39274185)
26. von Hahn T, Stopik D, Koch M, Wiedenmann B, Dignass A. Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus. Digestion 2005;71:141-4. (Pubitemid 40910933)
27. Yoshikawa H, Iwasa K, Satoh K, Takamori M. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun 1997;10:11-6. (Pubitemid 27110303)
28. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187-90.
29. Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M. Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis. Brain Dev 2009;31:634-7.
30. Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008;1132:254-63. (Pubitemid 351841343)
31. Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 2008;47:731-6. (Pubitemid 351936221)
32. Timerman AP, Ogunbumni E, Freund E, Wiederrecht G, Marks AR, Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506- binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993;268: 22992-9. (Pubitemid 23328003)
33. Davies TH, Ning YM, Sanchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8. (Pubitemid 40223631)
34. Araga S, Xu L, Nakashima K, Villain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J 2000;14:185-96. (Pubitemid 30051536)
35. Kang SY, Lee JS, Choi JC, Kang JH. Myasthenia gravis appearing after thymectomy: a case report and review of the literature. J Clin Neurol 2007;3:158-60.
36. Ahlberg R, Yi Q, Pirskanen R, Matell G, Swerup C, Rieber EP, et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 1994;44:1732-7. (Pubitemid 24286657)
37. Ragheb S, Bealmear B, Lisak R. Cell-surface expression of lymphocyte activation markers in myasthenia gravis. Autoimmunity 1999;31:55-66. (Pubitemid 32454571)
38. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183:3561-7.
39. Hoek KL, Carlesso G, Clark ES, Khan WN. Absence of mature peripheral B cell populations in mice with concomitant defects in B cell receptor and BAFF-R signaling. J Immunol 2009;183:5630-3.
40. Li X, Xiao BG, Xi JY, Lu CZ, Lu JH. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol 2008;126:180-8.
41. Kato A, Xiao H, Chustz RT, Liu MC, Schleimer RP. Local release of B cell-activating factor of the TNF family after segmental allergen challenge of allergic subjects. J Allergy Clin Immunol 2009;123:369-75.
42. Hamzaoui A, Chelbi H, Sassi FH, Hamzaoui K. Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement. Oxid Med Cell Longev 2010;3:122-8.
43. Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 2008;195:108-15.